Dr. Ann Partridge on Aggressive Breast Cancer in Younger Women
Partridge says that the current school of thought is younger women should be treated the same as older women with breast cancer, though younger women tend to develop more aggressive breast cancer with more nodal involvement.
Ann Partridge, MD, MPH, breast medical oncologist, Dana-Farber Cancer Institute, discusses the treatment of young women with breast cancer versus older women with breast cancer. Partridge says that the current school of thought is younger women should be treated the same as older women with breast cancer, though younger women tend to develop more aggressive breast cancer with more nodal involvement. Partridge says this is likely due to them not undergoing screening the same as older women with breast cancer.
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
